Linked Life Data

20383212

Source:http://linkedlifedata.com/resource/pubmed/id/20383212

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2011-1-12
pubmed:abstractText
We investigated clinical factors that affected the clearance of tacrolimus (FK506) administered by continuous drip infusion to children who had received allogeneic hematopoietic SCT. Blood FK506 levels were measured every day in 27 patients in an attempt to adjust the dose to maintain the target range (10-15 ng/mL). Patients who developed engraftment syndrome (ES) and acute GVHD and patients less than 7 years of age showed a higher FK506 clearance calculated from body weight (BW) for 5 or more consecutive days compared with the control groups. A time-course study showed that the occurrence of ES, but not acute GVHD, was related to increased clearance of FK506. When calculated from body surface area (BSA), a significant increase in FK506 clearance was observed in patients with ES, but not in those less than 7 years of age. FK506 clearance was not influenced by CYP3A5, multidrug resistance 1 or ABCG2 genotypes. None of the clinical parameters affected blood FK506 levels. Determination of the FK506 dose on the basis of frequent monitoring of the blood concentration seems to minimize the serious adverse effects induced by the immunosuppressant. It may be more accurate to dose FK506 according to BSA rather than BW for pediatric patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1476-5365
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
90-7
pubmed:meshHeading
pubmed-meshheading:20383212-ATP-Binding Cassette Transporters, pubmed-meshheading:20383212-Adolescent, pubmed-meshheading:20383212-Aging, pubmed-meshheading:20383212-Anoxia, pubmed-meshheading:20383212-Child, pubmed-meshheading:20383212-Child, Preschool, pubmed-meshheading:20383212-Cytochrome P-450 CYP3A, pubmed-meshheading:20383212-Drug Dosage Calculations, pubmed-meshheading:20383212-Erythema, pubmed-meshheading:20383212-Female, pubmed-meshheading:20383212-Fever, pubmed-meshheading:20383212-Graft vs Host Disease, pubmed-meshheading:20383212-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:20383212-Humans, pubmed-meshheading:20383212-Immunosuppressive Agents, pubmed-meshheading:20383212-Infant, pubmed-meshheading:20383212-Male, pubmed-meshheading:20383212-Metabolic Clearance Rate, pubmed-meshheading:20383212-Neoplasm Proteins, pubmed-meshheading:20383212-P-Glycoprotein, pubmed-meshheading:20383212-Polymorphism, Genetic, pubmed-meshheading:20383212-Pulmonary Eosinophilia, pubmed-meshheading:20383212-Syndrome, pubmed-meshheading:20383212-Tacrolimus, pubmed-meshheading:20383212-Weight Gain
pubmed:year
2011
pubmed:articleTitle
Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT.
pubmed:affiliation
Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
pubmed:publicationType
Journal Article, Comparative Study